Objective-To examine in vitro the ability of several drugs to protect against deleterious effects of peroxynitrite, a cytotoxic agent formed by reaction of nitric oxide with superoxide radical, that may be generated in the rheumatoid joint and could cause joint damage. Methods-The ability of several drugs to protect against such possible toxic actions of peroxynitrite as inactivation of Gl-antiproteinase and nitration of tyrosine was evaluated.
In chronic inflammatory diseases such as rheumatoid arthritis (RA) and inflammatory bowel disease, there is known to be overproduction of oxygen derived species such as superoxide radical, O2*.1 There is also considerable evidence that production of nitric oxide (NO") is increased-for example from measurements of increased nitric oxide synthase activity and demonstration of increased concentrations of nitrite/nitrate in body fluids from patients with RA.2A Nitric oxide reacts with a very high rate constant with 02--to give peroxynitrite (ONOO-).5 6 Peroxynitrite can be directly cytotoxic' 7 and it may also decompose at physiological pH to give a range of noxious products with reactivities resembling those of hydroxyl radicals (OH), nitrogen dioxide (NO2%), and nitronium ion (NO2+).8
Addition of peroxynitrite to tissues and biological fluids leads to nitration of aromatic amino acid residues, and the presence of these may be a 'marker' of peroxynitrite mediated (NO" dependent) damage in vivo.6 9-11 Indeed, nitrotyrosine is present in plasma and synovial fluid from patients with RA, but it was not detected in healthy control subjects.'2 Nitration of tyrosine residues on proteins may interfere with cell signal transduction by tyrosine phosphorylation/dephosphorylation.'3 Peroxynitrite also inactivates otl-antiproteinase, the major inhibitor of serine proteases (such as elastase) in human body fluids,7 14 and considerable inactivation of otl-antiproteinase has been shown to occur in the inflamed rheumatoid joint. '5 RA is treated by the use of a number of drugs, including non-steroidal antiinflammatory drugs (NSAIDs) such as aspirin and indomethacin,.and slower acting 'disease modifying' drugs, such as penicillamine and sulphasalazine, the mechanism of action of which is not always clear.
We have examined the ability of a range of drugs used in the treatment of RA to protect against damage by ONOO-. Two measures of damage that may be relevant to events in vivo were used: ability of the drug to prevent inactivation of ca1-antiproteinase by ONOO-, and ability of the drug to inhibit the nitration of tyrosine by ONOO-.
Materials and methods

REAGENTS
N-succinyl (ala)3-p-nitroanilide (SANA), catalase (type C40), elastase (E0258), al-antiproteinase (A9024), DL-tyrosine, and the antiinflammatory drugs were from Sigma Chemical Corp, Poole, Dorset, UK. Solutions of sulindac, paracetamol, ibuprofen, diclofenac, ampicillin, and tetracycline were made up in distilled water; those of indomethacin, tolmetin, flurbiprofen, sulphasalazine, sulphapyridine, and piroxicam were made up in water with minimum potassium hydroxide added to ensure solution. Salicylate, 5-aminosalicylate, aurothioglucose, penicillamine, and penicillamine disulphide were dissolved in 500 mmol/l potassium dihydrogen phosphate-dipotassium 34Whiteman, Kaur, Haliwell hydrogen phosphate (KH2PO4-K2HPO4) buffer pH 7-4; phenylbutazone was dissolved in 0 4% (w/v) sodium carbonate. Solutions were made up freshly every day and diluted with distilled water to obtain the required drug concentrations.
PEROXYNITRITE SYNTHESIS6
Five millilitres of an acidic solution (0-6 mol/l hydrochloric acid) of hydrogen peroxide (H202) 0 7 mol/l was mixed with 5 ml of potassium nitrite 0-6 mol/l on ice for one second and the reaction quenched with 5 ml of ice cold sodium hydroxide 1-2 moll. The stock was then frozen overnight (-20°C) and the top layer of the solution collected for the experiment. Concentrations of stock ONOOwere redetermined before each experiment using a molar absorption coefficient of 1670 (moll)-1 cm-' at 302 nm.6
MEASUREMENT OF TYROSINE NITRATION DL-Tyrosine solutions were made up to a final concentration of 10 mmolI by dissolving the required amount in 8 ml of water with 250 ,l of 10% (w/v) potassium hydroxide followed by 250 pl of 5% phosphoric acid and dilution to 10 ml by the addition of 1-5 ml of water. Tyrosine solution 0 1 ml together with 0 1 ml of a solution of the compound to be tested was added to a plastic test tube containing 0 795 ml of buffer (500 mmol/l K2HPO4-KH2PO4 pH 7 4) and incubated in a water bath at 37°C for 15 minutes. After this time peroxynitrite (typically 5 gl) was added to a final concentration of 1 mmol/I and the tubes were vortexed for 15 seconds and incubated for a further 15 minutes. The pH was measured after the addition of peroxynitrite and found to be between 7-4 and 7-5.
Formation of 3-nitrotyrosine was measured by high performance liquid chromatography (HPLC), rather than spectrophotometrically, to avoid interference as a result of the generation of chromogen from the drugs. Measurement of 3-nitrotyrosine was performed essentially as described previously8 using a Spherisorb 5 ,um ODS2 C18 column (25 cm X 4-6 mm) (HPLC Technology, Wellington House, Cheshire, UK) with a guard column C,8 cartridge (Hibar, BDH, Poole, UK). The eluent was 500 mmolI K2HPO4-KH2PO4 pH 3-01, with 20% methanol (v/v) at a flow rate of 1 ml min-' through a Polymer Laboratories pump (Essex Road, Church Stretten, Shropshire, UK); the ultraviolet detector was set at 274 mm (sensitivity 0-02). The 3-nitrotyrosine detected was confirmed by spiking with standards. Peak heights of tyrosine and 3-nitrotyrosine were measured and concentrations calculated from a standard curve.
PREVENTION OF Ct1-ANTIPROTEINASE
INACTIVATION
Elastase and al-antiproteinase were measured essentially as described previously.'6 al-Antiproteinase was dissolved in phosphate buffered saline, pH 7-4 (140 mmol/l sodium chloride, 2-7 mmol/l potassium chloride, 16 mmol/I disodium hydrogen phosphate, 2-9 mmol/l KH2PO4) to a concentration of 4 mg/ml and elastase was dissolved in the same buffer to a final concentration of 5 mg/ml. The volume of ot,-antiproteinase required to inhibit elastase by 80-90% (typically 60-70 gl) was added to buffer (500 mmol/I K2HPO4-KH2PO4 pH 7A4), with or without 0-1 ml of compound to be tested, to give a volume of 0 945 ml, and incubated in a water bath at 37°C for 15 minutes, when peroxynitrite (typically 5 j.l) was added to give a final concentration of 0 5 mmol/l. The sample was vortexed for 10 seconds and incubated for five minutes, elastase (usually 50 ,ul) was added and the sample further incubated at 37°C for 15 minutes, followed by addition of 2-0 ml of buffer. Then after 15 minutes, 0 1 ml of elastase substrate (SANA) was added and the rate of reaction followed at 410 nm for 30 seconds.
Results
INACTIVATION OF ctl-ANTIPROTEINASE:
PROTECTION BY DRUGS As expected,7 14 addition of ONOO-to al-antiproteinase led to inactivation of the ability of otl-antiproteinase to inhibit elastase. The inactivation was complete within five minutes at pH 7*4 (data not shown).
The extent of inactivation increased with ONOO-concentration and a five minute incubation time with 0 5 mmol/l ONOO-was selected for further studies. Investigation of the possibility that other constituents of the ONOO-solution (such as NO3-and H202, which can be present in were involved in the inactivation demonstrated that catalase (final concentration 103 U/ml) had no effect on inactivation of otl-antiproteinase by ONOO-, and that, when the ONOO-solution was added to buffer and incubated for five minutes at 37°C before the addition of aol-antiproteinase, the resulting 'decomposed ONOO-' solution (which still contains all the other contaminants6) had no effect on oxt-antiproteinase (data not shown). Figure 1 summarises the ability of a range of drugs to protect ac,-antiproteinase against inactivation by ONOO-. There was wide variation in the protective effects seen. Significant protection was observed with penicillamine, paracetamol, indomethacin, 5-aminosalicylate, diclofenac, naproxen, and tolmetin, but flurbiprofen, salicylate, sulphasalazine, sulindac, aurothioglucose, ibuprofen, and penicillamine disulphide were weakly effective. Sulphapyridine had no protective effect: indeed, it seemed to aggravate inactivation of otl-antiproteinase. We also tested the action of tetracycline, as this antibiotic has previously been found to exert antioxidant activity in vitro,'7 and found it to be a good inhibitor of damage to otl-antiproteinase by ONOO-, whereas ampicillin was not (fig 1) . Several drugs underwent changes in colour after the addition of ONOO-. Diclofenac and paracetamol developed yellow chromogens. The yellow colour of tetracycline deepened to orange/yellow after the addition of ONOOand became yellow/brown during the incubation. 5-Aminosalicylate developed a purple/ pink colour and purple precipitate after ONOO-addition, and this darkened to a purple/brown colour during the incubation. Phenylbutazone produced a slightly cloudy solution after the addition of ONOO-. None of these colour changes interfered with spectrophotometric measurement of elastase activity. All experiments were accompanied by controls '16 to ensure that the drugs tested had no effect on the assay procedures used to measure oal-antiproteinase-that is, they did not directly inhibit elastase, nor did they interfere with inhibition of elastase by oxl-antiproteinase. These controls were negative for the drugs listed here, except that naproxen inhibited elastase activity slightly: this was corrected for using appropriate controls. Piroxicam 10 mmol/l and phenylbutazone 1 0 mmol/l markedly inhibited elastase, while flufenamic acid 1-0 mmol/l inhibited the action of al-antiproteinase; data for these drugs are not presented. Addition of the drugs listed in figure 1 to the reaction mixtures after five minutes ofincubation of oal-antiproteinase with ONOO-had no effect-that is, the drugs could not reactivate cKl-antiproteinase after it had been inactivated by ONOO-. Figure 2 shows the concentration dependence of the protective action of those drugs shown to be most effective in the 'screen' (fig 1) . Most protective drugs were active at concentrations of 100 pmol/1-much less than the concentration of ONOO-used (0 5 mmol/l). However, even at 1 mmol/l concentrations, most drugs were unable to protect al-antiproteinase completely: the most effective were penicillamine and tetracycline.
NITRATION OF TYROSINE BY ONOO: PREVENTION BY DRUGS
None of the drugs tested coeluted with nitrotyrosine on HPLC or otherwise interfered with the HPLC analysis. Figure 3 summarises the ability of the various anti-inflammatory drugs to inhibit the nitration of tyrosine to 3-nitrotyrosine by exposure to ONOO-at pH 74.4611 18 19 Salicylate, tolmetin, sulphasalazine, sulphapyridine, ampicillin, ibuprofen, sulindac, penicillamine disulphide, naproxen, aurothioglucose, and flurbiprofen were fairly weak inhibitors, whereas paracetamol, flufenamic acid, piroxicam, diclofenac, tetracycline, 5-aminosalicylate, phenylbutazone, penicillamine, and indomethacin were more effective. Indeed, paracetamol, 5-aminosalicylate, and penicillamine prevented nitration completely at a concentration equimolar to that of ONOO-. Figure 4 shows the concentration dependence of inhibition by the drugs found to be most effective in the first screen (fig 3) . Effects were seen at concentrations of prmol/, compared with 1 mmol/l ONOO-. 398-405.
